Citigroup’s Impact BioMedical IBO Stock Holding History

Citigroup’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Sell	1 -352	-100%	-$208	﹤0.01%	6351
2026 Q1	$212	Buy	353 +352	+35,200%	+$176	﹤0.01%	5575
2025 Q4	$1	Sell	1 -3,395	-100%	-$1.8K	﹤0.01%	6004
2025 Q3	$2.26K	Sell	3,396 -5,388	-61%	-$3.4K	﹤0.01%	5455
2025 Q2	$5.68K	Buy	+8,784	New	+$4.93K	﹤0.01%	5262

Other funds holding IBO

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

GTAM

Global Trust Asset Management West Palm Beach, Florida $320M AUM 83.68% 1-Year Est. Return

CFFP

Center for Financial Planning Southfied, Michigan $1.07B AUM 18.98% 1-Year Est. Return

Citigroup's IBO Position: Q2 2026 in Review

Citigroup reduced its Impact BioMedical (IBO) stake by 100% in Q2 2026, selling an estimated $208 and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6351.

Citigroup first reported a position in IBO in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.68K in Q2 2025. 4 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

Citigroup held 1 share of Impact BioMedical worth $0 as of Q2 2026.
Citigroup sold 352 Impact BioMedical shares in Q2 2026, an estimated $208.
Impact BioMedical made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #6351 holding.
Citigroup first reported a position in Impact BioMedical in Q2 2025 and has held it in 5 quarters since.
Citigroup's Impact BioMedical position peaked at $5.68K in Q2 2025.
4 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.